Ascendis Pharma A/S reported revenue of EUR 247.50 million for the fourth quarter (Q4) of 2025 and EUR 720.13 million for the full year (FY) 2025. Gross profit for Q4 2025 was EUR 223.90 million, while full-year gross profit reached EUR 625.22 million. Research and development expenses were EUR 78.15 million in Q4 and EUR 303.62 million for the full year. Selling, general, and administrative expenses totaled EUR 135.86 million in Q4 and EUR 457.87 million for FY 2025. The company reported a net loss of EUR 34 million, or EUR 0.55 per share (basic and diluted), for Q4 2025. For the full year, the net loss was EUR 228 million, or EUR 3.76 per share (basic and diluted), representing a significant reduction compared to the previous year. As of December 31, 2025, cash and cash equivalents stood at EUR 616 million. The company had 61,977,408 ordinary shares outstanding, including 597,096 ordinary shares represented by ADSs held by the company. Ascendis Pharma held a conference call and webcast to discuss the results and ongoing activities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653231-en) on February 11, 2026, and is solely responsible for the information contained therein.